Home Nav
Nextech Invest Logo

PRIVATE COMPANIES

Cleave Biosciences

Cleave Biosciences
Clinical Phase I

Small molecule inhibitors targeting protein homeostasis

Burlingame, CA, USA

ImaginAb

ImaginAb
Clinical Phase II

Antibody fragments for imaging of cancer

Inglewood, CA, USA

MolecularMD

MolecularMD
Market

Cancer genotyping for targeted cancer therapies

Portland, OR, USA

Neon Therapeutics

Neon Therapeutics
Clinical Phase I

Neoantigen based cancer vaccines

Cambridge, MA, USA

Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems. Cleave’s CB-5083 is a first-in-class, oral inhibitor of p97, a critical enzyme that controls various aspects of protein homeostasis. P97 inhibition is a novel approach that has the potential to treat a wide range of cancers, including both solid tumors and hematologic malignancies. CB-5083 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of multiple myeloma. 


For more information contact Alfred Scheidegger


Cleave Biosciences, 866 Malcolm Road, Suite 100, Burlingame, CA 94010, USA
www.cleavebio.com

ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized for clinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.

Since its founding in 2007, the ImaginAb antibody fragments are moving towards clinical use for unmet needs in cancer and immunology, with first clinical projects in the area of prostate cancer (targeting PSMA: Prostate-Specific Membrane Antigen) and prostate, bladder and pancreatic (targeting PSCA: Prostate Stem cell antigen). ImaginAb is also developing a range of pre-clinical research reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies to develop companion imaging agents for therapeutic antibody products.

 

Please find a short introductory video here: http://youtu.be/yzSLIrJeCzE

The company has won and successfully completed the milestones of a Phase I SBIR contract with the National Cancer Institute and of programs in a number of major imaging and pharmaceutical company contracts.

Based in Inglewood, CA, ImaginAb collaborates extensively with UCLA, City of Hope and leading institutions in the United States and abroad.


For more information contact Thilo Schroeder


ImaginAb, Inc., 440 Hindry Ave., Suite E, Inglewood, CA 90301, USA
www.imaginab.com

MolecularMD is a vertically integrated molecular diagnostics company focusing on oncology. Founded in 2005, it provides molecular testing to enable clinical decisions for the use of the right targeted cancer therapeutic based on genetic mutations determined from a patient sample. In addition, it allows for quantitatively monitoring the effect of the therapeutic to allow switching to a different therapeutic at the onset of resistance. The major focus has been on providing testing for clinical trials of novel targeted cancer therapies. In addition, the company is developing companion diagnostics and provides testing to medical doctors.


For more information contact Alfred Scheidegger


MolecularMD, 1341 SW Custer Drive, Portland, OR 97219, USA
www.molecularmd.com

Neon Therapeutics is a leading company in the development of neoantigen based cancer therapies. Their programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need. Neon Therapeutics' lead program, NEO-PV-01, a personalized neoantigen vaccine, has entered clinical development with a first study in combination with Opdivo (nivolumab) in patients with metastatic melanoma, non-small cell lung cancer and bladder cancer.


For more information contact Thilo Schroeder


Neon Therapeutics, 40 Erie Street, Suite 110, Cambridge, MA 02139, USA
www.neontherapeutics.com

Peloton Therapeutics

Peloton Therapeutics
Clinical Phase I

Small-molecule programs with a distinct target and mechanism of action

Dallas, TX, USA

Founded by Professor Steven L. McKnight, Chairman of Biochemistry at The University of Texas Southwestern Medical Center (UT Southwestern), Peloton Therapeutics represents a unique combination of innovative science, talented researchers, and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline comprised of small-molecule programs, each with a distinct target and mechanism of action. The Company’s vision is to become a major biotech presence in Dallas by leveraging great science, high-caliber people, and the long-term support of Texas-based research institutions.


For more information contact Thilo Schroeder


Peloton Therapeutics, Inc., 2330 Inwood Road, Suite 226, Dallas, TX 75235-7323, USA
www.pelotontherapeutics.com

EXITED AND PUBLIC COMPANIES

 Agensys

Agensys
Acquired

Fully human antibody drug conjugates for pancreatic cancer


Illinois, USA

Blueprint Medicines

Blueprint Medicines
IPO

Highly selective kinase inhibitors for genomically defined cancer subsets


Cambridge, MA, USA

Ganymed Pharmaceuticals

Ganymed Pharmaceuticals
Acquired

Ideal monoclonal antibodies for cancer treatment


Mainz, Germany

Jounce Therapeutics

Jounce Therapeutics
IPO

Immunotherapeutics to create highly durable cancer treatments


Cambridge, MA, USA

Agensys is a biotechnology company specializing in therapeutic antibody research and development in cancer. It has selected candidate targets by applying differential gene-expression technology to human tissues, and identified 30 proprietary drug targets in 14 cancer types. It has abundant experience in using its optimized hybridoma method to generate fully human monoclonal antibodies. In November 2007 Astellas US Holding, Inc., the US subsidiary of Astellas Pharma Inc., acquired Agensys.


For more information contact Alfred Scheidegger


Astellas Pharma US, Inc., Illinois, USA
www.astellas.us

Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically-defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets. Blueprint Medicines was founded in 2011 and was initially financed by Third Rock Ventures and Fidelity Bioscience with corporate headquarters in Cambridge, Massachusetts.


For more information contact Thilo Schroeder


Blueprint Medicines, Inc., 38 Sidney Street, Suite 200, Cambridge, MA 02139, USA
www.blueprintmedicines.com

Ganymed Pharmaceuticals is a leading biopharmaceutical company offering smart antibody therapies for ideal targets in solid cancers. The company's discovery engine is one of the industry's most powerful integrated approaches to building an antibody cancer pipeline. A multi-centre, first-in-man, clinical-phase I study with Ganymed's Claudiximab antibody in patients with metastatic adenocarcinoma of the stomach and the lower esophagus has been successfully concluded. The company has five further antibody projects in non-clinical development in solid cancers with high unmet medical need, including melanomas, prostate cancers, lung cancers, breast cancers, colorectal cancers and cancers of the head and neck. Founded in 2001 as a spin-off of the Universities of Mainz and Zurich, the company is located in Mainz, Germany, and has 70 employees. In August 2008 ,the majority of the company shares were sold to ATS. In October 2016, the company was acquired by Astellas Pharma. 


For more information contact Alfred Scheidegger


Ganymed Pharmaceuticals AG, Freiligrathstrasse 12, 55131 Mainz, Germany
www.ganymed-pharmaceuticals.de

Jounce Therapeutics is discovering and developing novel cancer immunotherapies designed to mobilize the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine has the potential to discover novel biological insights to drive the development of game-changing immunotherapy treatments with highly durable responses, extending and improving patients' quality of life.

 

Jounce integrates industry-leading translational science insights at the very start of its programs allowing us to select the right targets, select patient populations with higher probability of success, and to achieve rapid Phase 1b proof-of-concept (POC) with greater effect size.

 

Jounce is identifying product candidates from two areas: (1) Next-generation T-cell checkpoint modulators and (2) Tumor Microenvironment (TME) modifiers. The company will advance programs that leverage insights and contributions from our founders as well as knowledge acquired from Jounce’s Translational Science Platform – thereby creating a sustainable "discovery to human POC" product engine. 


For more information contact Thilo Schroeder


Jounce Therapeutics, Inc., 1030 Massachusetts Avenue, Cambridge, MA 02138, USA
www.jouncetx.com

Kura Oncology

Kura Oncology
IPO

Small molecules that target cancer signaling pathways


La Jolla, CA, USA

MacroGenics

MacroGenics
Full Exit

Antibodies for cancer immunotherapy


Rockville, MD, USA

Palyon Medical

Palyon Medical
Liquidated

Implantable drug pumps for palliative care and diabetes


Santa Clarita, CA, USA

Sunesis Pharmaceuticals

Sunesis Pharmaceuticals
Partial Exit

Small molecules for acute myeloid leukemia


South San Francisco, CA, USA

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura Oncology brings together a proven team of drug developers and biotech entrepreneurs. Kura Oncology’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. 


For more information contact Thilo Schroeder


Kura Oncology, 11119 North Torrey Pines Road, Suite 125, La Jolla, CA 92037, USA
www.kuraoncology.com

Since its founding in 2000, MacroGenics has focused on applying its world-class antibody capabilities to discovering, developing and delivering to patients novel biologics for the treatment of cancer, autoimmune disorders and infectious diseases. Over 130 dedicated team members are committed to the use of breakthrough science to create life-changing medicines. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART™) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc.


For more information contact Alfred Scheidegger


MacroGenics, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA
www.macrogenics.com

Palyon Medical was a medical device company based in Santa Clarita, California developing technologies for the treatment of chronic pain, spasticity, and other acute and chronic diseases. The company was founded in 2004 in New York, USA. The company has been liquidated.   


For more information contact Alfred Scheidegger


Palyon Medical Corporation, 28368 Constellation Road, Unit 390, Santa Clarita, CA 91355, USA

Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new oncology therapies for the treatment of solid and hematologic cancers. Founded in 1998 in South San Francisco, California, USA, the company has built a highly experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer, and is traded on NASDAQ (SNSS).


For more information contact Thilo Schroeder


Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080, USA
www.sunesis.com

TeLoRmedix

TeLoRmedix
Sale of shares

Targeted immunity in cancer and other diseases


Bioggio, Switzerland

TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals
Full Exit

Small molecule Smac mimetics for treatment of cancers


Malvern, PA, USA

Tracon Pharmaceuticals

Tracon Pharmaceuticals
IPO

Antibodies targeting endoglin in cancer angiogenesis


San Diego, CA, USA

TeLoRmedix was a clinical-stage biopharmaceutical company that specializes in targeted immunity in the treatment of cancer and other diseases. The company's lead product was moving toward clinical development for the localized treatment of bladder cancer, and will thus satisfy an as-yet unmet medical need. TeLoRmedix also has additional programmes for autoimmune diseases in the pipeline. Founded in October 2007, the Switzerland-based company is led by a experienced management team and backed by a consortium of leading global investors. In 2015, the company was acquired by UroGen Pharma. 


TeLoRmedix SA, Via della Posta 10, 6934 Bioggio, Switzerland

TetraLogic Pharmaceuticals, a publicly traded (NASDAQ: TLOG) biopharmaceutical company, is a leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Smac mimetics are a new class of targeted drugs that mimic Smac (Second mitochondrial-derived activator of caspases) and specifically induce cancer cell death and inhibit fundamental mechanisms of cancer cell survival and resistance. TetraLogic's lead Smac mimetic drug, TL32711, is in clinical development for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies. TetraLogic Pharmaceuticals was founded in 2003 with corporate headquarters in Malvern, Pennsylvania.


For more information contact Alfred Scheidegger


TetraLogic Pharmaceuticals, Inc., 343 Phoenixville Pike, Malvern, PA 19355, USA
www.tetralogicpharma.com

Tracon Pharmaceuticals is a privately held biopharmaceutical company that develops targeted therapies against cancer and related diseases. The company has an experienced development team and leverages collaboratively funded clinical studies in a large number of indications. The current pipeline has three clinical-stage product candidates, each addressing a unique cellular process that is expected to complement first and second line standard of care therapy. The lead product, TRC105, is an antibody that inhibits angiogenesis, tumor cell growth, and cancer metastasis by binding to CD105. TRC102 is a small molecule that reverses resistance to chemotherapeutics. Tracon was founded in San Diego, USA in 2005.


For more information contact Alfred Scheidegger


Tracon Pharmaceuticals, 8910 University Center Lane, Suite 700, San Diego, CA 92122, USA
www.traconpharma.com

ASCO Annual Meeting

02.06. – 06.06.2017

Chicago

  • 14.06.2017

    Kura Oncology presents preliminary clinical and preclinical...

  • 07.06.2017

    Kura Oncology announces data presentations for tipifarnib...

  • 05.06.2017

    Blueprint Medicines announces new Phase 1 clinical data...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close